Herantis Pharma Oyj (HEL:HRTIS)

Finland · Delayed Price · Currency is EUR

2.100

-0.030 (-1.41%)

At close: Feb 27, 2026

44.83% (1Y)

Market Cap	54.46M
Revenue (ttm)	n/a
Net Income (ttm)	-5.45M
Shares Out	25.93M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,123
Average Volume	41,710
Open	2.130
Previous Close	2.130
Day's Range	2.100 - 2.140
52-Week Range	1.200 - 3.870
Beta	0.40
RSI	46.50
Earnings Date	Mar 5, 2026

About Herantis Pharma Oyj

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2008

Employees 13

Stock Exchange Nasdaq Helsinki

Ticker Symbol HRTIS

Full Company Profile